Ascletis Pharma Statistics

Total Valuation

Ascletis Pharma has a market cap or net worth of HKD 8.29 billion. The enterprise value is 6.22 billion.

Market Cap	8.29B
Enterprise Value	6.22B

Important Dates

The next estimated earnings date is Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Ascletis Pharma has 962.85 million shares outstanding. The number of shares has decreased by -6.75% in one year.

Current Share Class	962.85M
Shares Outstanding	962.85M
Shares Change (YoY)	-6.75%
Shares Change (QoQ)	-2.92%
Owned by Insiders (%)	64.62%
Owned by Institutions (%)	1.11%
Float	131.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6,071.86
PB Ratio	3.96
P/TBV Ratio	3.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-19.42
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-17.01

Financial Position

The company has a current ratio of 12.88, with a Debt / Equity ratio of 0.00.

Current Ratio	12.88
Quick Ratio	12.82
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	-1,658.33

Financial Efficiency

Return on equity (ROE) is -13.97% and return on invested capital (ROIC) is -11.70%.

Return on Equity (ROE)	-13.97%
Return on Assets (ROA)	-10.96%
Return on Invested Capital (ROIC)	-11.70%
Return on Capital Employed (ROCE)	-20.52%
Revenue Per Employee	5,911
Profits Per Employee	-1.39M
Employee Count	231
Asset Turnover	0.00
Inventory Turnover	0.10

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +912.94% in the last 52 weeks. The beta is 0.36, so Ascletis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.36
52-Week Price Change	+912.94%
50-Day Moving Average	7.37
200-Day Moving Average	4.44
Relative Strength Index (RSI)	50.71
Average Volume (20 Days)	6,868,843

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ascletis Pharma had revenue of HKD 1.37 million and -320.25 million in losses. Loss per share was -0.32.

Revenue	1.37M
Gross Profit	782,167
Operating Income	-430.60M
Pretax Income	-320.25M
Net Income	-320.25M
EBITDA	-415.51M
EBIT	-430.60M
Loss Per Share	-0.32

Full Income Statement

Balance Sheet

The company has 2.08 billion in cash and 8.12 million in debt, giving a net cash position of 2.07 billion or 2.15 per share.

Cash & Cash Equivalents	2.08B
Total Debt	8.12M
Net Cash	2.07B
Net Cash Per Share	2.15
Equity (Book Value)	2.09B
Book Value Per Share	2.15
Working Capital	1.93B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -363.50 million and capital expenditures -2.23 million, giving a free cash flow of -365.73 million.

Operating Cash Flow	-363.50M
Capital Expenditures	-2.23M
Free Cash Flow	-365.73M
FCF Per Share	-0.38

Full Cash Flow Statement

Margins

Gross Margin	57.29%
Operating Margin	-31,538.04%
Pretax Margin	-23,455.65%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ascletis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.75%
Shareholder Yield	n/a
Earnings Yield	-3.86%
FCF Yield	-4.41%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascletis Pharma has an Altman Z-Score of 4.29 and a Piotroski F-Score of 1.

Altman Z-Score	4.29
Piotroski F-Score	1